The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

U.S. equities rose at midday on optimism the new tariffs threatened by President Trump won't be as severe as initially believed.

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near future ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

The VDH and Scott are advocating for people to get their vaccinations before winter. Scott said he has received his COVID ...

We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...

For Nigeria, it has provided unhindered market access to the USA, but Mr Trump now demands reciprocity in trade. He has asked ...

Robert F. Kennedy Jr. petitioned the F.D.A. to revoke authorization of the shots at a time when they were in high demand and ...

Albert Bourla and other healthcare CEOs talked about the efficacy of vaccines and how public health could take a big turn for ...

The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect ...

Four years from now, what might we be saying about what we just lived through? The possibilities seem endless.

Moderna MRNA provided an update on its financial outlook and pipeline progress at the J.P. Morgan Healthcare Conference. At ...